首页> 外文期刊>International Journal of Pharmaceutics >Design and evaluation of a mucoadhesive therapeutic agent delivery system for postoperative chemotherapy in superficial bladder cancer.
【24h】

Design and evaluation of a mucoadhesive therapeutic agent delivery system for postoperative chemotherapy in superficial bladder cancer.

机译:用于浅表性膀胱癌术后化疗的粘膜粘附治疗剂输送系统的设计和评估。

获取原文
获取原文并翻译 | 示例
           

摘要

The most common treatment method is known as the transurethral resection (TUR) for the therapy of bladder cancer. Unfortunately, because of the recurrency of the tumoral tissues after TUR the chemotherapy or immunotherapy should be performed. In these kind of therapies the pharmacotherapeutics are infused intravesically into the bladder after TUR periodically (i.e. upto 6--36 weeks, each week). But these therapies are having very big problems (i.e. disturbancy to patients, adjustment of the suitable dosage, loss of active agents without using etc.). An alternative approach can be proposed as to design a pharmacotherapeutic agent delivery system, which will supply the suitable dosage of the agent for a certain time period to solve those problems. In this study; the pharmacotherapeutic agent (i.e. Mytomycin-C) delivery system was prepared by using a mucoadhesive polymer (i.e. chitosan) in the form of cylindirical geometry to facilitate the insertion of the carrier for in vivo studies. The chitosan carriers were prepared by cross-linking during the solvent evaporation technique. In the preparation of the chitosan carriers the chitosan polymers with different molecular weights, different amounts of cross-linker (i.e. glutaraldehyde) and different amounts of pharmacotherapeutic agent were used to obtain desired attachment onto the bladder wall and optimum release rate of the agent. On the other hand because of the gelous structure of the chitosan, the swelling behaviour of the polymer was evaluated by gravimetric determinations in aqueous media periodically.
机译:最常见的治疗方法称为经尿道切除术(TUR),用于治疗膀胱癌。不幸的是,由于TUR后肿瘤组织的复发,应该进行化学疗法或免疫疗法。在这类疗法中,定期(TUR)每周(即长达6--36周)将药物治疗药物膀胱内注入膀胱。但是这些疗法具有很大的问题(即对患者的困扰,调整合适的剂量,不使用而损失活性剂等)。可以提出一种替代方法来设计药物治疗剂输送系统,该系统将在一定时期内提供合适剂量的药物以解决这些问题。在这个研究中;通过使用圆柱形几何形状的粘膜粘附性聚合物(即壳聚糖)来制备药物治疗剂(即Myomyycin-C)递送系统,以利于载体的插入以进行体内研究。通过在溶剂蒸发技术中交联来制备壳聚糖载体。在壳聚糖载体的制备中,使用具有不同分子量,不同量的交联剂(即戊二醛)和不同量的药物治疗剂的壳聚糖聚合物来获得期望的附着在膀胱壁上和最佳的药物释放速率。另一方面,由于壳聚糖的凝胶状结构,通过在水性介质中定期进行重量分析来评估聚合物的溶胀行为。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号